Seeking to replace blockbuster drugs that will soon lose patent protection, drug-maker AbbVie purchased a biotech firm for ...

AbbVie will acquire the clinical-stage biotech’s pipeline of candidates for inflammatory and immunological diseases.

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a ...

AbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.

AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in ​more than five ...

AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a Reuters report ...

While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (Adalumymab-ryvk), ...

The last time I spoke about AbbVie Inc. (ABBV) it was in a Seeking Alpha article entitled as "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating." For this article I ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...